Clinical Trials
51 trialsNCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT04373369 2025-11-03
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT05420636 2025-07-30
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Phase 2 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT04032704 2025-03-10
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 2 Terminated
NCT04923776 2024-12-30
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Columbia University
Phase 2 Terminated
NCT04951115 2024-11-26
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT01904253 2024-09-05
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT01284348 2024-08-29
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04352413 2024-03-07
A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Terminated
NCT04308785 2023-10-23
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT05027867 2023-08-16
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Kartos Therapeutics, Inc.
Phase 2 Terminated
NCT03662074 2023-08-02
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT03406715 2023-03-30
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02963090 2023-02-15
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Terminated
NCT01266018 2022-10-25
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Ludwig Institute for Cancer Research
Phase 2 Terminated
NCT02934503 2021-11-16
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NYU Langone Health
Phase 2 Terminated
NCT02722369 2021-03-18
STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
University College, London
Phase 2 Terminated
NCT03724253 2020-10-23
NeoFIND
Advanced Accelerator Applications
Phase 2 Terminated
NCT01803269 2020-06-26
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Phase 2 Terminated
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT02062632 2019-10-01
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
Phase 2 Terminated
NCT02109016 2019-07-29
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
Clovis Oncology, Inc.
Phase 2 Terminated
NCT03366675 2018-11-27
AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]
Samsung Medical Center
Phase 2 Terminated
NCT02688907 2018-09-20
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
Samsung Medical Center
Phase 2 Terminated
NCT03106155 2018-09-20
[SUKSES-D]
Samsung Medical Center
Phase 2 Terminated
NCT00953459 2018-07-26
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT02161419 2018-06-25
CONCEPT-SCLC
Bayer
Phase 2 Terminated
NCT00265200 2018-03-05
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
University of Louisville
Phase 2 Terminated
NCT00003496 2017-09-28
Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
Burzynski Research Institute
Phase 2 Terminated
NCT00454324 2017-07-11
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01719861 2017-04-17
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT02351505 2016-05-16
Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00087048 2016-03-22
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00299390 2015-12-31
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
Bayer
Phase 2 Terminated
NCT01159327 2015-11-11
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
National Cancer Center, Korea
Phase 2 Terminated
NCT01421316 2015-06-04
Hair-sparing Whole Brain Radiotherapy
University Hospital, Ghent
Phase 2 Terminated
NCT01313663 2014-10-27
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
GlaxoSmithKline
Phase 2 Terminated
NCT00084487 2014-05-23
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003847 2013-09-05
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
Vertex Pharmaceuticals Incorporated
Phase 2 Terminated
NCT00977561 2013-02-25
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
Pfizer
Phase 2 Terminated
NCT00776295 2013-01-24
Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00544674 2012-12-10
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
Proacta, Incorporated
Phase 2 Terminated
NCT00324558 2012-06-08
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Terminated
NCT00216216 2011-05-02
Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00494026 2009-11-20
Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)
Eli Lilly and Company
Phase 2 Terminated
NCT00475657 2009-05-29
Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT00435578 2009-04-30
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Threshold Pharmaceuticals
Phase 2 Terminated